BYON4228, A PAN-ALLELIC SIRPa BLOCKING ANTIBODY WITH A FAVORABLE PRE-CLINICAL SAFETY PROFILE, ENHANCES ANTI-TUMOR IMMUNITY IN VITRO AND IN VIVO

JOURNAL FOR IMMUNOTHERAPY OF CANCER(2022)

Cited 0|Views17
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined